A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study

Prostate

Volumn 71, Issue 14, 2011, Pages 1587-1594

  Abdollah, Firas ^a,b   Schmitges, Jan ^a   Sun, Maxine ^a   Tian, Zhe ^a   Briganti, Alberto ^b   Shariat, Shahrokh F ^c   Perrotte, Paul ^a,d   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

lymph node excision; neoplasms pathology; prostatic neoplasms surgery

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; ADENOCARCINOMA; CANCER GRADING; CANCER REGISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM;

EID: 80052084668     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21376     Document Type: Article

References (18)

1. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Accessed 9/7/2010. http://www.nccn.org/professionals/physician-gls/PDF/prostate.pdf.
2. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479. (Pubitemid 43779173)
3. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K,. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009; 27: 100-105.
4. Masterson TA, Bianco FJ, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT,. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175: 1320-1324; discussion 1324-1325.
5. Joslyn SA, Konety BR,. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68: 121-125. (Pubitemid 44037727)
6. Berglund RK, Sadetsky N, Duchane J, Carroll PR, Klein EA,. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: Results from CaPSURE. J Urol 2007; 177: 526-529; discussion 529-530.
7. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML,. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005; 173: 1121-1125. (Pubitemid 40380516)
8. Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA,. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology 2008; 71: 141-145. (Pubitemid 351173260)
9. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, et al. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007., based on November 2006 SEER data submission, posted to the SEER Web Site.
10. Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF, Briganti A, Gallina A, Capitanio U, Colombo R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 53: 794-802. 2008.
11. Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75: 118-124.
12. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
13. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, et al. Guideline for the management of clinically localized prostate cancer. J Urol 2007; 177: 2106-2131. (Pubitemid 46726449)
14. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-1803. (Pubitemid 37254931)
15. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
16. Konety BR, Joslyn SA, O'Donnell MA,. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169: 946-950. (Pubitemid 36188131)
17. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675. (Pubitemid 32120143)
18. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J,. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253. (Pubitemid 41535365)